Nanostics reports study results for prostate cancer test

2019 10 16 20 31 7121 Cancer Cells Prostate 400

Nanostics reported results on Thursday of a clinical validation study showing that its machine learning-based ClarityDX Prostate test predicted clinically significant cancer in men that are at risk of the disease.

The test's machine-learning algorithm combines data from two biological biomarkers and three clinical biomarkers to generate a risk score for clinically significant prostate cancer.

It is intended to be used as a reflex test for men with elevated levels of PSA to help physicians and patients make a more informed decision about whether to proceed with a biopsy, Nanostics said.

In a clinical study, the test demonstrated 94% sensitivity, 37% specificity, 49% positive predictive value, and 90% negative predictive value for predicting clinically significant prostate cancer, the firm said.

The results of the study are being submitted to a peer-reviewed publication, the company added.

Page 1 of 8
Next Page